Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation

Growth Hormone and IGF Research

Volumn 16, Issue 2, 2006, Pages 101-107

  van der Klaauw, A A ^a   Bax, J J ^a   Roelfsema, F ^a   Bleeker, G B ^a   Holman, E R ^a   Corssmit, E P M ^a   van der Wall, E E ^a   Smit, J W A ^a   Romijn, J A ^a   Pereira, A M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acromegaly; Follow up; Valvular regurgitation

Indexed keywords

OCTREOTIDE;

ACROMEGALY; ADULT; AORTA VALVE REGURGITATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; MITRAL VALVE REGURGITATION; ORTHOPEDIC SURGERY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ACROMEGALY; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; PREVALENCE;

EID: 33646816784     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2006.02.002     Document Type: Article

References (21)

1. Clayton R.N. Cardiovascular function in acromegaly. Endocr. Rev. 24 (2003) 272-277
2. Colao A., Ferone D., Marzullo P., and Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr. Rev. 25 (2004) 102-152
3. Sacca L., Cittadini A., and Fazio S. Growth hormone and the heart. Endocr. Rev. 15 (1994) 555-573
4. Colao A., Cuocolo A., Marzullo P., et al. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J. Clin. Endocrinol. Metab. 86 (2001) 1551-1557
5. Pereira A.M., van Thiel S.W., Lindner J.R., et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. J. Clin. Endocrinol. Metab. 89 (2004) 71-75
6. Colao A., Spinelli L., Marzullo P., et al. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J. Clin. Endocrinol. Metab. 88 (2003) 3196-3201
7. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J. Am. Soc. Echocardiogr. 2 (1989) 358-367
8. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol. 57 (1986) 450-458
9. Vitale G., Galderisi M., Pivonello R., et al. Prevalence and determinants of left ventricular hypertrophy in acromegaly: impact of different methods of indexing left ventricular mass. Clin. Endocrinol. (Oxf) 60 (2004) 343-349
10. Perry G.J., Helmcke F., Nanda N.C., Byard C., and Soto B. Evaluation of aortic insufficiency by Doppler color flow mapping. J. Am. Coll. Cardiol. 9 (1987) 952-959
11. Thomas J.D. How leaky is that mitral valve? Simplified Doppler methods to measure regurgitant orifice area. Circulation 95 (1997) 548-550
12. Singh J.P., Evans J.C., Levy D., et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham heart study). Am. J. Cardiol. 83 (1999) 897-902
13. Rippe J., Fishbein M.C., Carabello B., et al. Primary myxomatous degeneration of cardiac valves. Clinical, pathological, haemodynamic, and echocardiographic profile. Br. Heart J. 44 (1980) 621-629
14. Enriquez-Sarano M., Avierinos J.F., Messika-Zeitoun D., et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N. Engl. J. Med. 352 (2005) 875-883
15. Minniti G., Jaffrain-Rea M.L., Moroni C., et al. Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics. Clin. Endocrinol. (Oxf) 49 (1998) 101-106
16. Vianna C.B., Vieira M.L., Mady C., et al. Treatment of acromegaly improves myocardial abnormalities. Am. Heart J. 143 (2002) 873-876
17. Colao A., Marzullo P., Ferone D., et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J. Clin. Endocrinol. Metab. 85 (2000) 3132-3140
18. Thompson B.J., Shang C.A., and Waters M.J. Identification of genes induced by growth hormone in rat liver using cDNA arrays. Endocrinology 141 (2000) 4321-4324
19. Rabkin E., Aikawa M., Stone J.R., et al. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 104 (2001) 2525-2532
20. R.A. Feelders, H.F. Savelkoul, W.W. de Herder, H. Hooijkaas, S.W. Lamberts, The cytokine network in acromegaly before and after pituitary surgery: growth hormone excess is associated with a reversible shift to the T-helper 1 cytokine response. Program of the 84th Annual Meeting of The Endocrine Society, San Francisco, CA, 2002, 76 (Abstract OR8-5).
21. Ilercil A., O'Grady M.J., Roman M.J., et al. Reference values for echocardiographic measurements in urban and rural populations of differing ethnicity: the strong heart study. J. Am. Soc. Echocardiogr. 14 (2001) 601-611